Sign In
Buy ACIU
$2.50
+0.100 (+4.17%)
At Close: Jun 22, 2026
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
06:00am, Wednesday, 02'nd Apr 2025
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
07:00am, Tuesday, 25'th Mar 2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
04:01pm, Monday, 24'th Mar 2025
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
07:00am, Thursday, 13'th Mar 2025
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Wednesday, 05'th Mar 2025
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for March 5th
07:40am, Wednesday, 05'th Mar 2025
PFLT, COMM, BGC, NLY and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on March 5, 2025.
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU)
10:36am, Thursday, 13'th Feb 2025
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
New Strong Buy Stocks for January 31st
06:56am, Friday, 31'st Jan 2025
ENS, SOPA, MC, SFIX and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
10:32am, Thursday, 14'th Nov 2024
AC Immune SA ACIU revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson's disease.
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
10:25am, Tuesday, 06'th Aug 2024
AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.42. This compares to loss of $0.22 per share a year ago.
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
03:10pm, Friday, 26'th Jul 2024
AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunoge
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease
07:00am, Thursday, 25'th Jul 2024
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain tr
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
07:00am, Tuesday, 28'th May 2024
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneeri
Alzheimer's vaccine licensing deal boosts AC Immune
08:47am, Monday, 13'th May 2024
AC Immune S.A. shares ACIU, -1.70% jumped more than 50% premarket on Monday after the Swiss biopharma company announced a licensing deal with Takeda Pharmaceutical Co. TAK, -0.90% for an experimental
